Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

  • Price (USD)15.79
  • Today's Change-1.20 / -7.06%
  • Shares traded344.74k
  • 1 Year change+28.69%
  • Beta0.5812
Data delayed at least 15 minutes, as of Nov 29 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

  • Revenue in USD (TTM)23.50m
  • Net income in USD-82.08m
  • Incorporated2012
  • Employees75.00
  • Location
    Aclaris Therapeutics Inc640 Lee Rd Ste 200WAYNE 19087-5636United StatesUSA
  • Phone+1 (484) 324-7933
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aclaristx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Deciphera Pharmaceuticals Inc121.89m-221.39m1.05bn280.00--2.80--8.62-3.46-3.461.825.540.25410.45815.90435,321.40-46.15-44.91-54.79-50.3195.04---181.63-556.775.32--0.00--128.45---12.56--92.99--
Arcutis Biotherapeutics Inc725.00k-310.77m1.05bn147.00--3.88--1,450.50-5.89-5.890.01394.450.0016--0.51924,931.97-69.37---74.01--62.90---42,864.14--13.27-34.850.4208-------52.09------
Opko Health Inc.1.22bn-316.95m1.08bn5.77k--0.664--0.8866-0.4545-0.45451.762.110.52579.546.45211,580.90-13.62-5.96-15.45-6.8027.9235.98-25.91-12.191.28-22.090.1338--23.649.69-198.55--6.43--
Kiniksa Pharmaceuticals Ltd177.04m142.57m1.10bn215.007.932.877.596.,446.5040.00-58.0645.85-66.5988.67--80.53-1,684.324.02--0.00------2.14--484.21--
Madrigal Pharmaceuticals Inc0.00-273.99m1.12bn71.00--104.74-----16.02-
ImmunoGen, Inc.95.61m-201.09m1.12bn106.00--6.30--11.73-0.8151-0.81510.38980.80640.2917--23.42901,952.80-61.35-35.82-91.37-48.56-----210.33-121.91---62.270.00---47.20---213.94------
P3 Health Partners Inc584.38m-91.04m1.13bn450.00------1.93-0.3737-0.37372.40-0.4026------1,298,623.00---------2.07---17.10-----1.69----232.80---17.32------
Aclaris Therapeutics Inc23.50m-82.08m1.13bn75.00--5.15--48.21-1.29-1.290.36813.300.0885--33.38313,333.30-30.91-45.25-33.26-50.3850.6623.19-349.26-1,612.49----0.00--4.30---77.63--5.83--
TG Therapeutics Inc5.03m-238.68m1.16bn186.00--11.54--230.81-1.78-1.780.03740.69130.016--7.2617,569.93-76.06-92.03-94.81-120.4490.61---4,749.83-14,968.54---27.800.4107--4,300.66113.05-24.60--3.11--
MannKind Corp76.23m-97.51m1.16bn348.00------15.23-0.385-0.3850.3001-0.90320.28654.105.83219,040.20-36.66-64.79-46.17-166.8530.7247.87-127.93-162.143.36-7.002.71--15.81-15.47-41.38--58.56--
Adaptive Biotechnologies Corp168.04m-221.50m1.16bn858.00--2.39--6.93-1.56-1.561.183.410.17913.137.70195,850.80-23.61---26.85--66.87---131.85--5.26--0.00--56.88---41.75------
Zentalis Pharmaceuticals Inc0.00-181.68m1.18bn177.00--2.49-----3.85-3.850.008.290.00----0.00-42.10---48.10--------------0.00-------34.69------
Imago Biosciences Inc0.00-61.64m1.21bn41.00--6.98-----1.83-1.830.005.100.00----0.00-29.09---30.74--------------0.00-------137.26------
Ligand Pharmaceuticals Inc241.67m-21.29m1.21bn154.00--1.4837.505.01-1.27-1.2714.3148.320.2081.563.731,569,305.00-1.8315.20-1.9816.8982.1388.16-8.8189.341.460.11360.0858--48.6620.522,014.17---14.83--
BridgeBio Pharma Inc88.66m-490.77m1.21bn576.00------13.66-3.35-3.350.6054-7.620.1174----153,930.60-65.73---77.58--95.11---559.83------2.99--745.14---25.36------
Data as of Nov 29 2022. Currency figures normalised to Aclaris Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

45.18%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 30 Sep 20224.40m6.60%
BVF Partners LPas of 30 Sep 20223.98m5.96%
Rock Springs Capital Management LPas of 30 Sep 20223.96m5.94%
BlackRock Fund Advisorsas of 30 Sep 20223.92m5.88%
Wellington Management Co. LLPas of 30 Sep 20223.45m5.18%
The Vanguard Group, Inc.as of 30 Sep 20222.79m4.18%
Commodore Capital LPas of 30 Sep 20222.41m3.62%
Holocene Advisors, LPas of 30 Sep 20222.06m3.09%
Point72 Asset Management LPas of 30 Sep 20221.85m2.78%
Laurion Capital Management LPas of 30 Sep 20221.30m1.96%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.